Related Experiment Video
Updated: Jan 1, 2026
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review
Peter Mohr1, Felix Kiecker2, Virtudes Soriano3
1Department of Dermatology, Elbe Kliniken, Stade, Germany.
Aim:
To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011-2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait.
Methods:
Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe.
Results:
Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy.
Conclusion:
Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma.
